REP 1001 (SEQ ID NO: 1) vs HSV-1




FIG. 1a

REP 2001 (SEQ ID NO: 2) vs HSV-1




FIG. 1b

REP 3007 (SEQ ID NO: 3) vs HSV-1





FIG. 1c


REP 2001 (SEQ ID NO: 2) vs HSV-1

FIG. 3a




REP 2002 vs HSV-1

FIG. 3b




REP 2003 vs HSV-1

FIG. 3c



REP 2004 vs HSV-1

FIG. 3d



REP 2016 (SEQ ID NO: 4) vs HSV-1




FIG. 8d

REP 2017 (SEQ ID NO: 5) vs HSV-1




FIG. 8e

REP 2018 (SEQ ID NO: 6) vs HSV-1




FIG. 8f

REP 2019 (SEQ ID NO: 7) vs HSV-1




FIG. 8g

REP 2020 (SEQ ID NO: 8) vs HSV-1




FIG. 8h

REP 2121 (SEQ ID NO: 9) vs HSV-1




FIG. 8i

Rep 1001 (SEQ ID NO: 1) vs HSV-2




FIG. 12a

REP 2001 (SEQ ID NO: 2) vs HSV-2




FIG. 12b

REP 3007 (SEQ ID NO: 3) vs HSV-2




FIG. 12c

REP 2001 (SEQ ID NO: 2) vs HSV-2

FIG. 14a




FIG. 14b




FIG. 14c






FIG. 14d









FIG. 17g

REP 2036 (Vitravene; SEQ ID NO: 10) vs CMV



REP 2036 (commercial Vitravene; SEQ ID NO: 1) vs CMV






FIG. 17i



Single and double stranded PS-ODNs can bind both HSV-1 and HIV-1



SEQUENCE COMPOSITION VS ANTI-HSV EFFICACY




FIG. 37a

Effect of sequence composition on efficiacy against HSV-1




FIG. 37b